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Abstract
Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy (TSE) of domestic and wild cervids in North America. To address
possible prevention regimens for CWD, we have used a mouse model system and the Rocky Mountain Laboratory (RML) mouse-adapted scrapie
prion strain to screen efficacy of potential vaccine candidates. Three peptides derived from the primary amino acid sequence of the prion protein
were conjugated to blue carrier protein (BCP) and formulated in an adjuvant containing M. avium subsp. avium. CL57/BL6 mice were vaccinated
and boosted with 50 g of the carrier protein–peptide conjugate formulation; all vaccines produced a humoral immune response as measured by
ELISA. Disease challenge with the RML scrapie prion strain revealed anti-prion activity was generated by the vaccine formulations as measured
by a delay in clinical disease onset and prolonged survivorship.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Prion; Chronic wasting disease (CWD); Transmissible spongiform encephalopathy (TSE); Scrapie; Vaccine

The unique self-protein nature of the transmissible spongiform
encephalopathy (TSE) infectious agent, the prion, presents a
major obstacle in the development of an effective vaccine to prevent these invariably fatal neurodegenerative diseases. A large
body of scientific evidence has revealed that a key event in the
transmission and propagation of TSE diseases is the formation
of a proteinase K (PK) resistant prion (denoted here as PrPres )
from the normal PK sensitive cellular form (PrPc ). The transformation from a non-pathogenic protein to the pathogenic form
occurs due to a post-translational protein refolding event that
changes PrPc from a protein that has high ␣-helical content to
one that has high ␤-sheet content [9]. The refolding process
can occur spontaneously, as with sporadic Cruezfledt Jakob disease (sCJD), or due to either a templating or seeding mechanism
whereby normal PrPc adopts a new conformation in the presence
of the incorrectly folded PrPres [1].
夽 Disclaimer: Mention of companies or commercial products does not imply
recommendation or endorsement by the USDA. Product names are mentioned
solely to report factually on available data and to provide specific information.
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When considering the entire TSE disease family, only the
cervid specific chronic wasting disease (CWD) and sheep
scrapie are readily transmissible to susceptible hosts through
horizontal transmission of infected animals or environmental
reservoirs of infectivity [6–8]. To develop a CWD management tool, we have evaluated peptide-based vaccine candidates
for eventual use in farmed and wild cervids. As an initial step
towards a CWD vaccine we selected a murine-based model,
the Rocky Mountain Laboratory (RML) mouse-adapted scrapie
prion strain, and peptides from regions of the prion protein that
are implicated in playing a role in PrPc to PrPres conversion.
Peptides from the primary amino acid sequence of the prion
protein were used that span the following regions; peptide 2,
112-AGAAAAGAVVGGKGGYMLGSAMSRPMMHFG-141,
peptide 4, 165-VDQYNNQNNFVHDC-178, and peptide 6,
141-GNDWEDRYYRENMYRYPNQ-159 160. Peptides were
synthesized by standard Fmoc strategies by Global Peptide
Services, Fort Collins, CO, USA. All peptides were >90% pure
as demonstrated by high-performance liquid chromatography.
All peptides, except peptide 4, were synthesized with either an
N-terminal or C-terminal linker containing a glycine cystine
for conjugation to blue carrier protein (BCP) (BioSonda
Santiago, Chile) using standard sulfosuccimnimidyl 4-(N-
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Table 1
Survival statistics
Group

Total animals

Survival range

Mean ± S.D.

AdjuvacTM

14
14
14
11
14

172–221
203–231
203–236
211–248
198–254

206
214
219
232
228

Positive
Vaccine 2
Vaccine 4
Vaccine 6

±
±
±
±
±

14
8
8
12
19

Survival median

Mann–Whitney vs. AdjuvacTM

Mann–Whitney vs. positive control

210
215
219
235
231

.1543
.0041
.0002
.0076

.0808
.0008
.056

maleimidomethyl) cycloheaxane-1-carboxylate (Sulfo-SMCC,
Pierce, Rockford, IL, USA) technology. Peptides 2 and 4 are
known to prevent the conversion of PrPc to PrPres in in vitro
conversion reactions [2,4]. The prion sequence of peptide 6
was chosen based on work by White et al. that demonstrated
administration of monoclonal antibodies with affinity to the
143–159 region of PrPc increased survivorship of RML scrapie
challenged mice from 150 days to >500 days [14].
Blue carrier protein was selected over the traditional Keyhole Limpet Hemocyanin (KLH) due to its reported improved
stability, high molecular weight, and enhanced immunogenicity [3]. All vaccine conjugates were made into a water in
oil emulsion using the adjuvant AdjuvacTM , developed at the
National Wildlife Research Center. AdjuvacTM is a modification of the Johne’s disease vaccine MycoparTM , containing M.
avium subsp. avium, (Fort Dodge Animal Health, Fort Dodge,
IA, USA).
Animal procedures were approved by the Institutional Animal Care and Use Committee of the USDA APHIS Wildlife
Services’, National Wildlife Research Center to assure all efforts
were made to minimize animal pain and discomfort during
the course of this study. C57/BL6 female mice were (Hilltop Labs, Scottsdale, AZ, USA) assigned at random into three
vaccine treatment groups, one negative control group and two
positive control groups. One positive control group received
only disease challenge; the second received both disease challenge and the vaccine adjuvant (AdjuvacTM ). Treatment animals
received two doses of vaccine (50 g of conjugate-carrier protein in both the prime and boost vaccinations) 32 days apart
via intramuscular injection in a hind leg. Fifteen days after the
booster injections animals were challenged via intraperitoneal
injection with 50 l of RML scrapie brain homogenate, graciously provided by Rocky Mountain Laboratories (Hamilton
MT, USA), diluted in PBS to a final concentration of 1/100
(w/v). All animals demonstrated well-characterized signs of
clinical mouse-adapted scrapie at the time of sacrifice as indicated by; lethargy, hyperactivity, polydipsia, ataxia, kyphosis
(hunched back), poor coat condition, and wasting. To confirm
TSE diagnosis and pathology of end-stage clinical animals, one
animal per group was selected for immuno-histochemistry (IHC)
analysis and at least two animals were selected for Western
blot.
Five mice per group were selected for blood collection to
monitor the production of antibodies towards the vaccine regimen by ELISA. To measure humoral immune response all
vaccine peptides were conjugated to maleimide activated bovine
serum albumin (BSA) (Pierce). Titers were defined as the maxi-

mal dilution at which the absorbance reading is two fold higher
than a typical background reading (0.070).
All vaccine constructs induced a humoral response. ELISA
results show a relatively strong immune response to vaccines, 2,
4, and 6 (Fig. 1). Linear regression analysis of humoral response
and median days until sacrifice shows no correlation between
antibody levels and length of time until sacrifice (R2 = 0.369).
Indeed, vaccine 4 prolonged survivorship by 20 days relative
to the positive control, more than any of the vaccine constructs
studied, but had the lowest measured titer. Vaccine 6 showed
the highest titers of all vaccines tested with titers measured by
peptide ELISAs of 1/25,000 12 days after the first prime vaccination (data not shown). Titers after both prime and boost
vaccinations were determined to be: Vaccine 2 = 1/32,000; vaccine 4 = 1/10,000; vaccine 6 = 1/40,000.
All vaccines improved the median of days to sacrifice relative
to both the positive control groups. Application of the nonparametric Mann–Whitney U-test to evaluate the null hypothesis
between the positive control groups and the vaccinate groups
demonstrated that vaccine 4 was the most successful, with vaccines 6 and 2 also showing significance at the 95% confidence
interval. The results of the statistical analysis are shown in
Table 1. The p value for all treatment groups increased when
vaccinates are compared with the positive control animals that
received only the RML scrapie challenge. Assessment of the
observed anti-PrPres protection based purely on the median days
until sacrifice and Kaplan–Meier survivor curves shown in Fig. 2
would suggest that vaccines 4 and 6 provided the highest degree
of protection against disease progression. Indeed, a comparison
of the 25 and 21 days increase in median days to sacrifice for vaccines 4 and 6, respectively correlates to a reduction in infectious

Fig. 1. IgG ELISA analysis of pre-challenge mice. Sera from three animals
per group were used to generate average ELISA signal ±S.E. Sera was diluted
1/4000. Vaccine peptides were conjugated to BSA prior to coating of ELISA
plate.
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Fig. 2. Kaplan–Meier survivor curves. Vaccination with PrP peptides–BCP conjugates formulated in AdjuvacTM slows RML mouse-adapted scrapie disease
progression relative to positive controls. The increase in incubation time is statistically relevant, 2, p = 0.0041, 4, p = 0.0002, and 6, p = 0.0076 (median survival
compared AdjuvacTM positive control).

prion dose of 1.5–2 logs (based on infectivity titrations of the
RML strain provided by Sue Priola and Anne Ward from Rocky
Mountain Laboratories). The apparent discrepancy between the
lower p value of vaccine 2 versus vaccine 6, p = 0.004 versus
p = 0.0076, respectively, can be accounted for in early sacrifices
of several animals from the vaccine 6 experimental group. Interestingly, the AdjuvacTM challenge group appeared to display a
slightly accelerated disease progression relative to the positive
control (parametric ANOVA, p = 0.07).
Most animals vaccinated with the vaccine 4 or vaccine 6
formulations showed a striking delay in onset of typical clinical symptoms. Few mice (<5) from these groups displayed
the typical kyphosis (hunched back), poor grooming, ataxic, or
polydipsia behaviors present in the positive control groups from
approximately days 200–214 p.i. After day 225 p.i., the majority
of the animals in these two groups had begun to exhibit clinical
symptoms that increased in severity and progressed in identical
fashion to the positive control groups.
None of the vaccines produced obvious behavioral effects in
any of the mice in the preclinical-phase of the disease, although
detailed study of induced cognitive deficits due to vaccination
were beyond the scope of this study. All animals in the study
(expect negative control group) displayed the characteristic signs
of mouse-adapted scrapie. The clinical signs and survival curves
all conform to RML mouse-adapted scrapie strain for the dosage
level used in this study, indicating that the challenge was successful. In addition, all end-stage clinical animals tested for PrPres
by western blot and IHC showed accumulation of high levels of
PrPres and spongiform neuronal pathology as shown in Fig. 3A
and B.
It must be noted that three animals from the same cage of
the vaccine 4 treatment group died during the course of this
study. Standard Western blot analysis of brains collected from
these animals showed no high level PrPres accumulation indicative of terminal stage clinical scrapie and these animals were
censored from the Kaplan–Meier and statistical analysis. Phosphotungesten Acid enrichment of PrPres from 200 l of brain a
10% (w/v%) homogenate and subsequent Western blot analysis did identify that PrPres was present at levels at least 50-fold
lower than a typical end-stage clinical animal (data not shown).
The exact cause of these fatalities is not known.

Fig. 3. (A) Immuno histochemistry of a positive control animal sacrificed
in the terminal stage of the disease displays typical spongiform change and
PrPres immuno staining. (B) Diagnostic western blot of two animals per group.
1 = Brain homogenate–proteinase K (PK). Lane 2 = negative brain + PK. Lanes
3 and 4 = AdjuvacTM control. Lanes 5 and 6 = positive control. Lanes 7 and
8 = group 2. Lanes 9 and 10 = group 4. Lanes 11 and 12 = group 6. The animal
in lane 9 died due to an undetermined illness at 152 days.

Although our active immunization approach did not result
in total protection against challenge from PrPres containing
brain homogenate, anti-prion effect as measured by increased
days until sacrifice and delay in onset of clinical signs was
observed in the vaccinated groups. These results are significant
as immune tolerance to the self prion antigen was at least partially abrogated in this study as measured by relatively high
ELISA values towards PrPc antigens for vaccines 2, 4, and 6.
The most comparable study by Schwarz et al. [12] required six
50 g peptide-KLH immunizations to generate antibody titers
as measured by ELISA of 1/1500. Use of an adjuvant using CpG
oligodeoxynucleotides to boost immune response to free prion
peptides has been reported as a successful strategy to overcome
immune tolerance [11]. A comparison of the antibody levels generated using the CpG adjuvant and free prion peptide approach
to this study suggests that both higher antibody titers and less
animal to animal immune response variability were obtained
using BCP and the AdjuvacTM formulation described herein.
BCP and AdjuvacTM adjuvant described here.
The titers generated by our active vaccination strategy were
not strongly correlated to overall anti-prion protection; suggesting that in addition to overcoming the self-tolerance problem, a
PrPc epitope must also be suitably identified that will generate
antibodies that have high affinity to PrPres . Vaccines 4 and 6
may present an example of this concept. The prion amino acid
sequence of vaccine 6, encompassing ␣-helix 1, includes the
N-terminal YYR motif shown to be solvent accessible in PrPres
[10]. The amino acid sequence of vaccine 4 is also immediately
C-terminal to the second PrPres solvent exposed YYR motif. The
proximity of the amino acid sequences used in vaccines 6 and
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4 to these PrPres solvent exposed regions may allow antibodies produced against the PrPc primary amino acid sequence to
bind to epitopes that are present in both the PrPc and PrPres and
induce T-cell mediated clearance of at least some level of PrPres
infectivity.
While several groups have previously reported prion peptidecarrier protein strategies for inducing an active immune response
to block the progression of TSEs, a fully successful study has
yet to be reported. Schwarz et al. reported similar improvements
in survival times as observed with our best performing vaccine
constructs. However, direct comparisons are not totally relevant
as the PrPres strain and route of challenge were different. Another
study by Magri et al. using prion peptides conjugated to the traditional KLH carrier protein in the hamsters 263K model system,
reported no statistical significance between the non-immunized
and vaccinated groups with respect to survival times due to high
standard deviation and small sample size. It is interesting to note
however that Magri et al. [5] did observe the longest median
increase in survival time with a peptide that overlaps with the
amino acid sequence of vaccine 6, again highlighting the importance of the 141–179 region. Our study improves on these results
by using a novel adjuvant and relatively new carrier protein to
increase longevity in scrapie challenged mice.
The observation that the AdjuvacTM adjuvant appeared to
slightly increase the progression of the disease was an unexpected corollary result of this vaccination study. An observation
that appears to conflict with a published report of a therapeutic
effect against prion disease progression by the administration
of complete Freund’s adjuvant alone [13]. The mechanism by
which an adjuvant composed of M. avium subsp. avium could
result in acceleration of PrPres replication and/or neuroinvasion
is unknown.
While we have demonstrated both an ability to overcome
immune tolerance and generate a subsequent anti-prion effect
by this vaccination method, a fully successful TSE vaccine
was not achieved; at least as assessed by the high dose RML
scrapie bolus challenge method used here. A better understanding of the structural features of PrPres present on infectious prion
particles and creation of vaccines the mimic PrPres structural features, will likely be needed to develop a truly efficacious CWD
vaccine.
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